Hsa_circ_0006916 Knockdown Represses the Development of Hepatocellular Carcinoma via Modulating miR-599/SRSF2 Axis Retraction
Condition: Hepatocellular Carcinoma Intervention: Drug: atezolizumab plus bevacizumab Sponsor: CHA University Recruiting
This study aims to determine the risk factors of recurrence beyond Milan criteria in patients with transplantable early hepatocellular carcinoma (HCC) after the first Radiofrequency ablation (RFA). 95 patients with newly diagnosed transplantable small HCC with single ≤ 3 cm were analyzed retrospectively. During the 39-month median follow-up period, 12 (21.8%) patients with HCC
British Journal of Cancer, Published online: 19 January 2022; doi:10.1038/s41416-022-01706-9Urine DNA biomarkers for hepatocellular carcinoma screening
Introduction Non-alcoholic fatty liver disease (NAFLD), a disorder characterised by pathological accumulation of non-visible free fatty acids and visible triglyceride in hepatocytes, is on the rise globally in both adult and paediatric populations.1 Evidence suggests that 20%–50% of the European Union and US populations exhibit features of NAFLD,2 driven by higher rates of obesity, insulin resistance and type 2 diabetes, and metabolic syndrome.3 Additionally, recognition of a growing number of patients with ‘lean NAFLD’ who are not obese, but have high levels of visceral fat, diets high in fats and carboh...
Telomerase reverse transcriptase (TERT) promoter mutations, resulting in increased TERT activity, are known to be associated with many different cancer types, including among 70%–80% of glioblastomas and 60% each of bladder carcinomas and hepatocellular carcinomas.1–3 Increased TERT activity has also been associated with several molecular features including rare rearrangements, duplications and amplifications.1 However, of all the molecular changes, mutations in the TERT promoter region are known to be the most frequent. They are often restricted to two hotspots, 124 and 146 base pairs upstream of the transcrip...
Since its identification, HCV has been considered one of the main causes of hepatitis and liver cancer. Currently, the molecular mechanisms of HCC development induced by HCV infection have not been sufficiently clarified. The recent discovery of novel treatments that inhibit HCV replication gave rise to new questions concerning HCC mechanisms. In particular, the HCV eradication mediated by new direct-acting antiviral (DAAs) drugs does not exclude the possibility of de novo HCC development; this finding opened more questions on the interplay between liver cells and the virus. Different groups have investigated the pathways ...
ConclusionsEsophageal cancer patients with male sex, middle esophagus and brain metastasis were more likely to have bone metastasis. Compared to patients with other metastatic sites such as liver, brain and lung, patients with bone metastasis had a worse prognosis. Our findings provide recommendations about clinical guidelines for esophageal cancer patients with bone metastasis.
Conclusion: Needle profile was the only factor associated with access-site complications in this study. Therefore, a needle with a smaller profile than an 18-G needle will reduce the incidence of complications at the access site.
Conclusion: Our data indicate that the expression of the glycolytic phenotype of metabolic markers, especially GLUT1 and MCT4, correlates with a more severe course of HCC occurring in NASH patients.Pathobiology
CONCLUSIONS: The results of this review show that SSRI use was associated with a 34% lower risk of HCC, which tend to be dose dependent. Further prospective studies are warranted to confirm these observations across the spectrum of chronic liver disease and hepatitis infection.PMID:35039907 | DOI:10.1007/s00228-021-03264-0